Results 131 to 140 of about 16,895 (259)

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double‐blind, placebo‐controlled, phase 3 trial (SYNCHRONIZE™‐1)

Diabetes, Obesity and Metabolism, Volume 28, Issue 1, Page 337-346, January 2026.
Abstract Aims Survodutide, a novel glucagon receptor and glucagon‐like peptide‐1 (GLP‐1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report
Carel W. le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M. Kloer, Lee M. Kaplan   +9 more
wiley   +1 more source

Neprilysin gene expression requires binding of the amyloid precursor protein intracellular domain to its promoter: implications for Alzheimer disease [PDF]

, 2008
Nikolai D. Belyaev, Natalia N. Nalivaeva, Natalia Z. Makova, Anthony J. Turner   +3 more
openalex   +1 more source

Acute Inhibition of Intestinal Neprilysin Enhances Insulin Secretion via GLP-1 Receptor Signaling in Male Mice

, 2023
Nathalie Esser, Thomas O. Mundinger, Breanne M. Barrow, Sakeneh Zraika   +3 more
openalex   +2 more sources

Prescription Pattern in Angiotensin Receptor Neprilysin Inhibitor is Associated with Heart Failure Events. [PDF]

, 2023
Wei-Tsung Wu, Shih‐Han Wang, Yalin Wang, Tsung‐Hsien Lin, Wen‐Ter Lai, Sheng‐Hsiung Sheu   +5 more
openalex   +1 more source

Neprilysin [PDF]

, 2020
openaire   +1 more source

Cardiovascular biomarkers and preeclampsia: A narrative review

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Preeclampsia (PE) is a complex pregnancy disorder linked to cardiovascular disease (CVD) through shared risk factors and epidemiological associations. Cardiovascular biomarkers are valuable for predicting, diagnosing and assessing PE, as well as estimating future CVD risk. This review explores current cardiovascular biomarkers used in clinical practice
Johana Ullmo, Madalina Nicoleta Nan, Mónica Cruz‐Lemini, Carmen Garrido‐Gimenez, Judit Platero, Álvaro García‐Osuna, Pablo García‐Manau, Marcel Twickler, Elisa Llurba   +8 more
wiley   +1 more source

Angiotensin Receptor-Neprilysin Inhibition.

Journal of cardiovascular pharmacology and therapeutics, 2018
The novel combination sacubitril/valsartan represents a new therapeutic approach in the management of heart failure. With the simultaneous blockage of the enzyme neprilysin (by sacubitril) and angiotensin II receptors (by valsartan), this combination reduces the degradation of natriuretic peptides and other counterregulatory peptide systems while ...
Ofer, Havakuk, Uri, Elkayam
openaire   +1 more source

Induction of ischaemic cardiomyopathy in mice without off‐target effects

Experimental Physiology, EarlyView.
Mark T. Waddingham, James T. Pearson
wiley   +1 more source

Albumin, urea‐to‐albumin ratio, or the albumin‐to‐creatinine ratio to predict outcomes in heart failure with mildly reduced ejection fraction

European Journal of Clinical Investigation, Volume 56, Issue 1, January 2026.
Among 2061 hospitalized HFmrEF patients, low albumin, albumin‐to‐creatinine ratios (ACR), and elevated urea‐to‐albumin ratios (UAR) independently predicted long‐term all‐cause mortality, but not HF‐related rehospitalization. The UAR and ACR did not provide a clinically significant predictive advantage over albumin levels alone. Abstract Background This
Alexander Schmitt, Ibrahim Akin, Marielen Reinhardt, Noah Abel, Felix Lau, Jonas Dudda, Mohammad Abumayyaleh, Kathrin Weidner, Thomas Bertsch, Daniel Duerschmied, Michael Behnes, Tobias Schupp   +11 more
wiley   +1 more source

Targeting Neprilysin (NEP) pathways: A potential new hope to defeat COVID-19 ghost

, 2020
Manar Mohammed El Tabaa, Maram Mohammed El Tabaa   +1 more
openalex   +2 more sources